MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - TSX:MDP - CA58410Q2036 - Common Stock
2.68 CAD
-0.01 (-0.37%)
MDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
MDP had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDP has a better Return On Assets (0.52%) than 77.42% of its industry peers.
With a decent Return On Equity value of 1.52%, MDP is doing good in the industry, outperforming 77.42% of the companies in the same industry.
The Return On Invested Capital of MDP (8.11%) is better than 90.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MDP is above the industry average of 7.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROIC | 8.11% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 0.76%, MDP is doing good in the industry, outperforming 70.97% of the companies in the same industry.
MDP has a Operating Margin of 7.99%. This is in the better half of the industry: MDP outperforms 77.42% of its industry peers.
MDP's Gross Margin of 52.55% is amongst the best of the industry. MDP outperforms 80.65% of its industry peers.
MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MDP has been increased compared to 1 year ago.
The number of shares outstanding for MDP has been increased compared to 5 years ago.
MDP has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.56, we must say that MDP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.56, MDP is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
The Debt to FCF ratio of MDP is 1.29, which is an excellent value as it means it would take MDP, only 1.29 years of fcf income to pay off all of its debts.
MDP's Debt to FCF ratio of 1.29 is amongst the best of the industry. MDP outperforms 93.55% of its industry peers.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MDP (0.00) is better than 90.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 0.56 |
ROIC/WACC0.92
WACC8.8%
2.3 Liquidity
A Current Ratio of 0.81 indicates that MDP may have some problems paying its short term obligations.
MDP's Current ratio of 0.81 is on the low side compared to the rest of the industry. MDP is outperformed by 87.10% of its industry peers.
A Quick Ratio of 0.37 indicates that MDP may have some problems paying its short term obligations.
MDP has a worse Quick ratio (0.37) than 87.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
The earnings per share for MDP have decreased strongly by -50.00% in the last year.
MDP shows a decrease in Revenue. In the last year, the revenue decreased by -2.87%.
MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
3.2 Future
The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.19% on average per year.
EPS Next Y-115.78%
EPS Next 2Y96.23%
EPS Next 3Y96.39%
EPS Next 5Y53.29%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 89.33, the valuation of MDP can be described as expensive.
Based on the Price/Earnings ratio, MDP is valued a bit cheaper than 77.42% of the companies in the same industry.
MDP is valuated expensively when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.16, the valuation of MDP can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 93.55% of the companies listed in the same industry.
MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89.33 | ||
| Fwd PE | 6.16 |
4.2 Price Multiples
MDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDP is cheaper than 93.55% of the companies in the same industry.
MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 87.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.61 | ||
| EV/EBITDA | 4.43 |
4.3 Compensation for Growth
MDP has a very decent profitability rating, which may justify a higher PE ratio.
MDP's earnings are expected to grow with 96.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y96.23%
EPS Next 3Y96.39%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (11/5/2025, 7:00:00 PM)
2.68
-0.01 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.1%
Inst Owner ChangeN/A
Ins Owners7.27%
Ins Owner ChangeN/A
Market Cap86.46M
Revenue(TTM)105.66M
Net Income(TTM)806.00K
Analysts82.22
Price Target6.3 (135.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.23%
Min EPS beat(2)58.46%
Max EPS beat(2)144%
EPS beat(4)3
Avg EPS beat(4)43.05%
Min EPS beat(4)-100%
Max EPS beat(4)144%
EPS beat(8)5
Avg EPS beat(8)4.43%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)10
Avg EPS beat(16)67.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.13%
Revenue beat(12)5
Avg Revenue beat(12)0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.71%
PT rev (1m)0%
PT rev (3m)-4.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)78.26%
EPS NY rev (1m)0%
EPS NY rev (3m)86.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89.33 | ||
| Fwd PE | 6.16 | ||
| P/S | 0.58 | ||
| P/FCF | 3.61 | ||
| P/OCF | 3.1 | ||
| P/B | 1.16 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.43 |
EPS(TTM)0.03
EY1.12%
EPS(NY)0.44
Fwd EY16.24%
FCF(TTM)0.74
FCFY27.69%
OCF(TTM)0.87
OCFY32.29%
SpS4.63
BVpS2.32
TBVpS-1.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.25
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROCE | 11.27% | ||
| ROIC | 8.11% | ||
| ROICexc | 9.27% | ||
| ROICexgc | N/A | ||
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% | ||
| FCFM | 16.03% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 34.4% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 2.18 | ||
| Cash Conversion | 118.79% | ||
| Profit Quality | 2101.86% | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z | 0.56 |
F-Score5
WACC8.8%
ROIC/WACC0.92
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-115.78%
EPS Next 2Y96.23%
EPS Next 3Y96.39%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.65%
EBIT Next 3Y60.67%
EBIT Next 5Y50.41%
FCF growth 1Y164.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y191.19%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA.
Can you provide the valuation status for MEDEXUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 6 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.